Morgan Stanley Celyad Oncology Sa Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.5 - $2.37 $9,100 - $43,134	-18,200 Reduced 99.45%	100 $0
Q4 2022 Feb 14, 2023	SELL	$0.49 - $1.08 $294 - $648	-600 Reduced 3.17%	18,300 $8,000
Q3 2022 Nov 14, 2022	SELL	$1.57 - $2.45 $1,570 - $2,450	-1,000 Reduced 5.03%	18,900 $26,000
Q2 2022 Oct 27, 2022	SELL	$1.55 - $2.32 $155 - $231	-100 Reduced 0.5%	19,900 $34,000
Q2 2022 Aug 15, 2022	SELL	$1.55 - $2.32 $155 - $231	-100 Reduced 0.5%	19,900 $34,000
Q1 2022 Oct 27, 2022	BUY	$1.72 - $4.08 $172 - $408	100 Added 0.5%	20,000 $49,000
Q1 2022 May 13, 2022	SELL	$1.72 - $4.08 $6,807 - $16,148	-3,958 Reduced 16.52%	20,000 $49,000
Q4 2021 Feb 14, 2022	SELL	$3.56 - $5.0 $3,068 - $4,310	-862 Reduced 3.47%	23,958 $88,000
Q3 2021 Nov 15, 2021	BUY	$3.88 - $5.25 $96,301 - $130,305	24,820 New	24,820 $102,000

Ticker CYAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,594,000
Market Cap $11.7M
Description
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.